49 clinical trials found.

Amyloidosis

• A Phase 1, Open Label, Dose Escalation Study of Intravenous Administration of Single Agent NEOD001 in Subjects with Light Chain (AL) Amyloidosis
• A Phase 3, Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of Dexamethasone Plus MLN9708 or Physician's Choice of Treatment Administered to Patients With Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis
• Phase II Study of the Combination of Bendamustine and Dexamethasone in Patients with Relapsed AL Amyloidosis

Brain Tumor

• A Prospective, Multi-center Trial of NovoTTF-100A Together With Temozolomide Compared to Temozolomide Alone in Patients with Newly Diagnosed GBM
• ACNS0331: A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy (18.00 Gy) and Chemotherapy in Children with Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial
• ACNS0332: Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/ PNET Patients
• ACNS0334: A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children < 36 Months Old with Intensive Induction Chemotherapy with Methotrexate Followed by Consolidation with Stem Cell Rescue vs. the Same Therapy without Methotrexate
• ACNS0822: A Randomized Phase II/III Study of Vorinostat and Local Irradiation OR Temozolomide and Local Irradiation OR Bevacizumab and Local Irradiation Followed by Maintenance Bevacizumab and Temozolomide in Children with Newly Diagnosed High-Grade Gliomas

Breast Cancer

• CALGB70305: A Randomized Study to Prevent Lymphedema in Women Treated for Breast Cancer
• NSABP B-47: A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
• NSABP B-49: A Phase III Clinical Trial Comparing the Combination of Docetaxel plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
• NSABP-B43: A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy

Colon Cancer

• CALGB 80702: A Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer

Colorectal Cancer

• Randomized Clinical Trial Evaluating the Impact Of Pretreatment With Metformin on Colorectal Cancer Stem Cells (CCSC) and Related Pharmacodynamic Markers

Crohn's Disease

• A Phase II Study To Evaluate The Efficacy And Safety Of 12 Weeks Of Treatment With Oral Cndo 201 Trichuris Suis Ova Suspension (Tso) As Compared To Placebo, Followed By A 12 Week Open- Label Treatment Period In Patients With Moderately To Severely Active Crohn's Disease

Endocrinology, Diabetes & Metabolism

• Vitamin D for established type 2 diabetes mellitus (DDM2)

Eosinophilic Esophagitis (EoE)

• ORAL BUDESONIDE SUSPENSION (OBS) IN ADOLESCENT AND YOUNG ADULT SUBJECTS (12-25 YEARS OF AGE) WITH EOSINOPHILIC ESOPHAGITIS: A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY WITH AN OPEN-LABEL EXTENSION

Head and Neck Cancer

• 09266B: Randomized Double-Blind Phase II Trial of Everolimus versus Placebo as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN)
• Phase 1/2 study of PX-866 and Cetuximab
• RTOG 0920 A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer

Heme Malignancies: Acute Myeloid Leukemia (AML)

• A Phase 2, Randomized, Open-Label Study of the Safety and Efficacy of Two Doses of Quizartinib (AC220; ASP2689) in Subjects with FLT3-ITD Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

Heme Malignancies: Leukemia

• AALL0631: A Phase III Study of Risk Directed Therapy for Infants with Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; IND#76431; NSC#617807)
• AALL07P1: A Phase II Pilot Trial of Bortezomib (PS-341, Velcade, IND# 58,443) in Combination with Intensive Re-Induction Therapy for Children with Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)
• AALL08B1: Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
• AALL1131: Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC# 606869) in the Very High Risk Stratum
• AAML1031L: A Phase III Randomized Trial for Patients with de novo AML using Bortezomib and Sorafenib (IND#114480; NSC# 681239, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD
• E2906: Phase III Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age =60 Years)
• Expanded Access Program of Ponatinib (AP24534) for Patients with Refractory Chronic Myeloid Leukemia (CML) or Ph+ Acute Lymphoblastic Leukemia (Ph+ ALL)

Heme Malignancies: Lymphoblastic Lymphoma

• AALL07P1: A Phase II Pilot Trial of Bortezomib (PS-341, Velcade, IND# 58,443) in Combination with Intensive Re-Induction Therapy for Children with Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)

Kidney Disease

• Aerobics, Weights and Renal Disease (AWARD) Trial

Liver Cancer

• E1208: A Phase III Randomized Trial of Chemoembolization with or without Sorafenib in Unresectable Hepatocellular Carcinoma (HCC) in Patients with and without Vascular Invasion

Lung Cancer

• A Phase II Study of L-BLP25 and Bevacizumab in Unresectable Stage IIIA and IIIB Non-Squamous Non-Small Cell Lung Cancer after Definitive Chemoradiation
• ACOSOG Z4099/RTOG 1021: A Randomized Phase III Study of Sublobar Resection (+/- Brachytherapy) versus Stereotactic Body Radiation Therapy in High Risk Patients with Stage I Non-Small Cell Lung Cancer (NSCLC)

Lymphoid Malignancy

• Pilot Study of Lymphoid Tumor Microenvironmental Dysruption Prior to Autologous Stem cell Transplantation

Multiple Myeloma

• A Phase II, Safety and Efficacy Study of Fixed Dose Radioimmunotherapy (Zevalin, Yttrium-90 Ibritumomab Tiuxetan) for Patients with Incomplete Response to Chemotherapy Prior to Autologous Stem Cell Transplant for Multiple Myeloma

Neuro-Oncology

• A Prospective, Multi-center Trial of NovoTTF-100A Together With Temozolomide Compared to Temozolomide Alone in Patients with Newly Diagnosed GBM
• ACNS0331: A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy (18.00 Gy) and Chemotherapy in Children with Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial
• ACNS0332: Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/ PNET Patients
• ACNS0822: A Randomized Phase II/III Study of Vorinostat and Local Irradiation OR Temozolomide and Local Irradiation OR Bevacizumab and Local Irradiation Followed by Maintenance Bevacizumab and Temozolomide in Children with Newly Diagnosed High-Grade Gliomas

Ovarian, Primary Peritoneal, Fallopian Tube Cancer

• A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12, Monthly Cycles Of Single Agent Paclitaxel or CT-2103 (IND#70177) Versus No Treatment Until Documented Relapse in Women with Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy GOG-0212

Prostate Cancer

• CALGB 90203: RANDOMIZED PHASE III STUDY OF NEO-ADJUVANT DOCETAXEL AND ANDROGEN DEPRIVATION PRIOR TO RADICAL PROSTATECTOMY VERSUS IMMEDIATE RADICAL PROSTATECTOMY IN PATIENTS WITH HIGH-RISK, CLINICALLY LOCALIZED PROSTATE CANCER
• E2809: Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy

Pulmonary Arterial Hypertension

• A Phase 2, Multi-Center, Open-label, Randomized, Parallel-Dose Study to Determine the Safety and Efficacy of AIR001 in Subjects with WHO Group 1 Pulmonary Arterial Hypertension
• A Phase 2, Placebo Controlled Double-Blind, Randomized, Clinical Study to Determine Safety, Tolerability and Efficacy of Pulsed, Inhaled Nitric Oxide (iNO) Verses Placebo as Add-On Therapy in Symptomatic Subjects with Pulmonary Arterial Hypertension (PAH)

Renal Cell Carcinoma

• HOG GU09-145: Phase I/II Study of BNC105P in Combination with Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors

Veno-Occlusive Disease (VOD)

• Defibrotide For Patients With Hepatic Veno-Occlusive Disease (VOD): A Treatment IND Study (Under CFR 312.34)

Wilms Tumor

• AREN0532: Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor
• AREN0534: Treatment for Patients with Bilateral, Multicentric, or Bilaterally-Predisposed Unilateral Wilms Tumor
• Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors